CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals.  Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue.  We also offer solutions that can help ease private company financial risk assessment.  Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively. 

A partial report preview for Cerevel Therapeutics Holdings Inc is shown below.  Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database.  To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

Cerevel Therapeutics Holdings Inc
222 Jacobs Street, Suite 200
Phone: (212) 284-2300p:212 284-2300 CAMBRIDGE, MA  02141  United States Fax: (302) 636-5454f:302 636-5454
This company was Merged or Acquired on 8/1/2024.
This company ceased filing statements with the SEC on 8/12/2024.
This company is no longer actively traded on any major stock exchange.
This is a Subsidiary, click here for the Parent Company
Business Summary
Cerevel Therapeutics Holdings, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on neuroscience that combines an understanding of disease-related biology and neurocircuitry of the brain with advanced chemistry and central nervous system (CNS) target receptor selective pharmacology to discover and design new therapies. It focuses on transform the lives of patients through the development of new therapies for neuroscience diseases, including schizophrenia, Alzheimer’s disease psychosis, epilepsy, panic disorder and Parkinson’s disease. Its pipeline candidates include Emraclidine, Darigabat, Tavapadon and CVL-871. Emraclidine is a positive allosteric modulator (PAM), that selectively targets the muscarinic acetylcholine 4 receptor subtype (M4). Darigabat is a PAM that selectively targets the alpha 2/3/5 subunits of the GABAA receptor. Tavapadon is a selective dopamine D1/D5 receptor partial agonist that it is developing for the treatment of Parkinson’s disease.

Scores and Ratings
FRISK®
Score		 Z''
Score		 PAYCE®
Score		 DBT
Index		 Moody's
Rating		 Fitch
Rating		 DBRS
Rating
-Yes-Yes---

Financials, News and Filings
Latest
Statement		 Last
Audit
News		 SEC
Filings		 Bankruptcy
Filings		 Suit &
Judgment
Filings		 Tax
Lien
Filings
3/31/202412/31/2023YesYes--Yes

Industries
SIC Code Description
8731 Commercial physical and biological research
6770 Blank checks

Officers and Directors

Title
Name
Age		 Title
Date		 Start
Date
Chairperson of the Board of Directors N. AnthonyColes 63 6/12/2023 12/1/2018
President, Chief Executive Officer, Member of the Board Ronald C.Renaud 55 6/12/2023 6/12/2023
Chief Financial Officer SusanAltschuller 42 5/15/2023 5/15/2023
12 additional Officers and Directors records available in full report.

Business Names
Business Name
Cerevel MA Securities Corp.
Cerevel Therapeutics, Inc.
Cerevel Therapeutics, LLC
Cerevel Therapeutics, LLC

General Information
Number of Employees: 355 (As of 3/31/2024)
Outstanding Shares: 182,194,722 (As of 4/26/2024)
Shareholders: 3
Stock Exchange: NASD
Federal Tax Id: 981533670
Fax Number: (302) 636-5454


Copyright © 2024 CreditRiskMonitor.com (Ticker: CRMZ). All rights reserved.     
By using this website, you accept the Terms of Use Agreement.
Wednesday, November 20, 2024